Top

Published in:

24-04-2024 | Diffuse Large B-Cell Lymphoma

Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?

Authors: Hua-Jay J. Cherng, MD, Alex Herrera, MD

Published in: Current Treatment Options in Oncology | Issue 5/2024

Opinion Statement

Diffuse large B-cell lymphoma (DLBCL) is a curable disease with variable outcomes due to underlying heterogeneous clinical and molecular features—features that are insufficiently characterized with our current tools. Due to these limitations, treatment largely remains a “one-size-fits-all” approach. Circulating tumor DNA (ctDNA) is a novel biomarker in cancers that is increasingly utilized for risk stratification and response assessment. ctDNA is readily detectable from the plasma of patients with DLBCL but has not yet been incorporated into clinical care to guide treatment. Here, we describe how ctDNA sequencing represents a promising technology in development to personalize the care of patients with DLBCL. We will review the different types of ctDNA assays being studied and the rapidly growing body of evidence supporting the utility of ctDNA in different treatment settings in DLBCL. Risk stratification by estimation of tumor burden and liquid genotyping, molecular response assessment during treatment, and monitoring for measurable residual disease (MRD) to identify therapy resistance and predict clinical relapse are all potential applications of ctDNA. It is time for clinical trials in DLBCL to utilize ctDNA as an integral biomarker for patient selection, response-adapted designs, and surrogate endpoints. As more ctDNA assays become commercially available for routine use, clinicians should consider liquid biopsy when treatment response is equivocal on imaging. Incorporating MRD may also guide decision-making if patients experience severe treatment toxicities. Though important barriers remain, we believe that ctDNA will soon be ready to transition from bench to bedside to individualize treatment for our patients with DLBCL.

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15 [cited 2022 Dec 26];140(11):1229–53. Available from: https://ashpublications.org/blood/article/140/11/1229/485458/The-International-Consensus-Classification-of.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022 36:7. 2022 Jun 22 [cited 2022 Dec 26];36(7):1720–48. Available from: https://www.nature.com/articles/s41375-022-01620-2.

Longo DL, Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, editor. https://doi.org/10.1056/NEJMra2027612. 2021 Mar 3 [cited 2022 Apr 1];384(9):842–58. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra2027612.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23 [cited 2019 Oct 18];116(12):2040–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20548096.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct [cited 2019 Oct 18];12(11):1013–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21940214.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New England Journal of Medicine. 1995 Dec 7 [cited 2020 Sep 23];333(23):1540–5. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199512073332305.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017 Dec 28 [cited 2020 Jul 26];377(26):2531–44. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1707447.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 2019 Jan 3 [cited 2020 Jul 26];380(1):45–56. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1804980.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020 Sep 19 [cited 2021 Mar 17];396(10254):839–52. Available from: http://www.thelancet.com/article/S0140673620313660/fulltext.

10.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed

11.

Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–8. https://doi.org/10.1182/blood.2019002729. ([cited 2023 Dec 24]).CrossRefPubMed

12.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. New England Journal of Medicine. 2022 Jan 27 [cited 2022 Apr 1];386(4):351–63. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2115304

13.

Alizadeh AA, Elsen MB, Davis RE, Ma CL, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.CrossRefPubMed

14.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23.CrossRefPubMedPubMedCentral

15.

Cherng HJJ, Westin J. Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2021 Jan 6;1–17. Available from: https://www.tandfonline.com/doi/abs/10.1080/10428194.2020.1869228.

16.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.CrossRefPubMed

17.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90.CrossRefPubMedPubMedCentral

18.

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.e14.CrossRefPubMedPubMedCentral

19.

Zhang MC, Tian S, Fu D, Chen SJ, Xu PP, Zhao WL. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41:1705-1716.e5. https://doi.org/10.1016/j.ccell.2023.09.004. ([cited 2023 Dec 24]).CrossRefPubMed

20.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. Vol. 32, Journal of Clinical Oncology. American Society of Clinical Oncology; 2014 [cited 2020 Sep 27]. p. 3059–67. Available from: /pmc/articles/PMC4979083/?report=abstract.

21.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2010 Apr 10 [cited 2020 Sep 27];28(11):1896–903. Available from: https://pubmed.ncbi.nlm.nih.gov/20212248/.

22.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024–34.CrossRefPubMed

23.

Le Gouill S, Casasnovas RO. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017 Jun 8 [cited 2022 Sep 23];129(23):3059–70. Available from: https://ashpublications.org/blood/article/129/23/3059/36036/Interim-PET-driven-strategy-in-de-novo-diffuse.

24.

El-Galaly TC, Jakobsen LH, Hutchings M, De Nully Brown P, Nilsson-Ehle H, Szekely E, et al. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol. 2015 Dec 1 [cited 2023 Dec 24];33(34):3993–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26438115/.

25.

Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, et al. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021;5(5):1283–90. https://doi.org/10.1182/bloodadvances.2020002690. ([cited 2023 Dec 24]).CrossRefPubMedPubMedCentral

26.

Cescon DW, Bratman S V., Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer 2020 1:3. 2020 Mar 20 [cited 2023 Dec 24];1(3):276–90. Available from: https://www.nature.com/articles/s43018-020-0043-5.

27.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells 1. Cancer Res. 2001 [cited 2023 Dec 27];61:1659–65. Available from: http://aacrjournals.org/cancerres/article-pdf/61/4/1659/3252577/ch040101659p.pdf.

28.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36(16):1631–41.CrossRefPubMed

29.

Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Annals of Oncology. 2009 Aug 1 [cited 2023 Dec 27];20(8):1408–13. Available from: http://www.annalsofoncology.org/article/S0923753419409575/fulltext.

30.

Kurtz DM, Green MR, Bratman S V., Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015 Jun 11 [cited 2020 Jul 26];125(24):3679–87. Available from: https://pubmed.ncbi.nlm.nih.gov/25887775/.

31.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep [cited 2023 Dec 27];14(9):985–90. Available from: https://pubmed.ncbi.nlm.nih.gov/18670422/.

32.

Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015 [cited 2020 Jul 26];16(5):541–9. Available from: https://pubmed.ncbi.nlm.nih.gov/25842160/.

33.

Ching T, Duncan ME, Newman-Eerkes T, McWhorter MME, Tracy JM, Steen MS, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020 Jun 30 [cited 2023 Dec 27];20(1):1–15. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-07077-9.

34.

Newman AM, Bratman S V., To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine 2014 20:5. 2014 Apr 6 [cited 2022 May 7];20(5):548–54. Available from: https://www.nature.com/articles/nm.3519.

35.

Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016 Nov 9 [cited 2020 Jul 26];8(364):364ra155–364ra155. Available from: https://stm.sciencemag.org/content/8/364/364ra155.

36.

Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017 Apr 6 [cited 2020 Aug 10];129(14):1947–57. Available from: https://ashpublications.org/blood/article-pdf/129/14/1947/1399720/blood719641.pdf.

37.

Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018 Aug 1 [cited 2023 Dec 31];8(8). Available from: https://pubmed.ncbi.nlm.nih.gov/30069017/.

38.

Le Goff E, Blanc-Durand P, Roulin L, Lafont C, Loyaux R, MBoumbae DL, et al. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. Br J Haematol. 2023 Jul 1 [cited 2023 Dec 22];202(1):54–64. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18809.

39.

Samorodnitsky E, Jewell BM, Hagopian R, Miya J, Wing MR, Lyon E, et al. Evaluation of hybridization capture versus amplicon‐based methods for whole‐exome sequencing. Hum Mutat. 2015 Sep 1 [cited 2023 Dec 31];36(9):903. Available from: /pmc/articles/PMC4832303/.

40.

Stokowski RP, Tabari E, Bogard P, Hacker C, Kameneva OK, Ji T, et al. Detection of early molecular response (EMR) and minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using a validated next generation sequencing (NGS) assay for the detection of tumor variants in circulating tumor (ct)DNA. Blood. 2022;140(Supplement 1):9257–8. https://doi.org/10.1182/blood-2022-162814. ([cited 2023 Dec 27]).CrossRef

41.

Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology 2016 34:5. 2016 Mar 28 [cited 2022 Nov 26];34(5):547–55. Available from: https://www.nature.com/articles/nbt.3520.

42.

•• Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology 2021 39:12. 2021 Jul 22 [cited 2022 Apr 2];39(12):1537–47. Available from: https://www.nature.com/articles/s41587-021-00981-w. This pivotal study established the viability of sequencing phased variants as an ultrasensitive method of detecting ctDNA and MRD in B-cell lymphomas but also solid tumors. PhasED-seq potentially is the most sensitive ctDNA assay in development in DLBCL.

43.

Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine 2020 26:7. 2020 Jun 1 [cited 2023 Dec 30];26(7):1114–24. Available from: https://www.nature.com/articles/s41591-020-0915-3.

44.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications 2017 8:1. 2017 Nov 6 [cited 2021 Dec 3];8(1):1–13. Available from: https://www.nature.com/articles/s41467-017-00965-y.

45.

Raman L, van der Linden M, de Vriendt C, van den Broeck B, Muylle K, Deeren D, et al. Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. Haematologica. 2022 Jan 1 [cited 2023 Dec 30];107(1):211–20. Available from: https://pubmed.ncbi.nlm.nih.gov/33299235/.

46.

Cherng HJJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 Aug 4 [cited 2022 Sep 24];140(5):504–15. Available from: https://ashpublications.org/blood/article/140/5/504/485178/Risk-assessment-with-low-pass-whole-genome.

47.

Narkhede MS, Tomassetti S, Iqbal M, Tin A, Rivero-Hinojosa S, George GV, et al. Role of circulating tumor DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma. Blood. 2023;142(Supplement 1):4376–4376. https://doi.org/10.1182/blood-2023-186603. ([cited 2023 Dec 30]).CrossRef

48.

Merryman RW, Rhoades J, Xiong K, Antel K, An HH, Redd RA, et al. A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL. Blood. 2023;142(Supplement 1):527–527. https://doi.org/10.1182/blood-2023-189962. ([cited 2023 Dec 30]).CrossRef

49.

Figaredo G, Martín-Muñoz A, Barrio S, Parrilla L, Campos-Martín Y, Poza M, et al. Genetic profiling of cell-free DNA in liquid biopsies: a complementary tool for the diagnosis of B-cell lymphomas and the surveillance of measurable residual disease. Cancers (Basel). 2023 Aug 1 [cited 2023 Dec 30];15(16). Available from: https://pubmed.ncbi.nlm.nih.gov/37627050/.

50.

Rivas-Delgado A, Nadeu F, Enjuanes A, Casanueva-Eliceiry S, Mozas P, Magnano L, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clinical Cancer Research. 2021;27(2):513–21. https://doi.org/10.1158/1078-0432.CCR-20-2558. ([cited 2023 Dec 31]).CrossRefPubMed

51.

•• Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139(12):1863–77. https://doi.org/10.1182/blood.2021012852. This is a comprehensive study using hybrid capture sequencing that covered the breadth of applications of ctDNA in DLBCL, including pre-treatment prognostication, liquid genotyping at baseline and relapse, assessment of molecular response, and detection of MRD.CrossRefPubMed

52.

Cherng HJJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, et al. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023;7(7):1137–45. https://doi.org/10.1182/bloodadvances.2022008174. ([cited 2023 Jun 26]).CrossRefPubMed

53.

Jardin F, Raghavan V, Tracy S, Balasubramanian S, Sehn LH, Flowers CR, et al. Plasma circulating tumor DNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: results from the POLARIX study. Blood. 2023;142(Supplement 1):169–169. https://doi.org/10.1182/blood-2023-178564. ([cited 2024 Jan 2]).CrossRef

54.

Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-Cell lymphoma. Clinical Cancer Research. 2016 Aug 1 [cited 2022 May 1];22(15):3801–9. Available from: https://aacrjournals.org/clincancerres/article/22/15/3801/79298/Molecular-Profile-and-FDG-PET-CT-Total-Metabolic.

55.

Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv. 2020 Mar 24 [cited 2022 May 1];4(6):1082–92. Available from: https://ashpublications.org/bloodadvances/article/4/6/1082/452720/SAKK38-07-study-integration-of-baseline-metabolic.

56.

Mikhaeel NG, Heymans MW, Eertink JJ, De Vet HCW, Boellaard R, Dührsen U, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol. 2022 [cited 2024 Jan 2];40(21):2352–60. Available from: https://pubmed.ncbi.nlm.nih.gov/35357901/.

57.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2018 Oct 1 [cited 2020 Jul 26];36(28):2845–53. Available from: https://pubmed.ncbi.nlm.nih.gov/30125215/.

58.

• Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2021;39(23):2605–16. This study strongly correlated ctDNA quantity with other markers of tumor burden as well as diagnosis-to-treatment interval, which is an important surrogate for the urgency of treatment initiation with many implications for clinical trials.CrossRefPubMedPubMedCentral

59.

Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018 Jun 1 [cited 2024 Jan 2];36(16):1603–10. Available from: https://pubmed.ncbi.nlm.nih.gov/29672223/.

60.

• Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019;178(3):699-713.e19. This study illustrates the utility of serial ctDNA assessment during therapy to continually adjust a patient’s risk calculation, particularly when complemented by other standard assessments.CrossRefPubMedPubMedCentral

61.

Herrera AF, McCord R, Kimes P, Jardin F, Lenz G, Trneny M, et al. Risk Profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): results from the POLARIX study. Blood. 2022;140(Supplement 1):1297–300. https://doi.org/10.1182/blood-2022-157559. ([cited 2024 Jan 2]).CrossRef

62.

Roschewski M, Kurtz DM, Westin J, Lynch RC, Macaulay C, Kuffer C, et al. MRD-negativity as a potential surrogate endpoint after frontline DLBCL therapy: pooled analysis of trials & implications for clinical trial design. Blood. 2022 Nov 15 [cited 2022 Nov 30];140(Supplement 1):785–6. Available from: https://ashpublications.org/blood/article/140/Supplement1/785/489983/MRD-Negativity-As-a-Potential-Surrogate-Endpoint

63.

Goldstein J, Kim WS, Yoon SE, Kim SJ, Roschewski M, Westin J, et al. Optimizing circulating tumor DNA limits of detection for DLBCL during first line therapy. Blood. 2023;142(Supplement 1):187–187. https://doi.org/10.1182/blood-2023-187759.CrossRef

64.

Roschewski M, Lindenberg L, Mena E, Lakhotia R, Melani C, Steinberg SM, et al. End-of-treatment response assessment after frontline therapy for aggressive B-cell lymphoma: landmark comparison of a singular PET/CT scan versus ultrasensitive circulating tumor DNA. Blood. 2023;142(Supplement 1):192–192. https://doi.org/10.1182/blood-2023-180007.CrossRef

65.

Lynch RC, Poh C, Ujjani CS, Warren EH, Smith SD, Shadman M, et al. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023;7(11):2449–58. https://doi.org/10.1182/bloodadvances.2022009145.CrossRefPubMed

66.

Herrera AF, Tracy S, Sehn LH, Jardin F, Lenz G, Trneny M, et al. Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study. https://doi.org/10.1200/JCO20234116_suppl7523. 2023 May 31;41(16_suppl):7523–7523.

67.

Kumar A, Westin J, Schuster SJ, Nowakowski GS, Lossos IS, Batlevi CL, et al. Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):46–7. https://doi.org/10.1182/blood-2020-138889.CrossRef

68.

•• Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. https://doi.org/10.1200/JCO2100377. 2021 Jun 16;JCO.21.00377. This study was one of the first to assess ctDNA dynamics early after CART19 infusion (with clonoSEQ) to demonstrate the utility of ctDNA sequencing after curative salvage therapies in R/R DLBCL.

69.

Dean EA, Kimmel GJ, Frank MJ, Bukhari A, Hossain NM, Jain MD, et al. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2023;7(16):4608–18. https://doi.org/10.1182/bloodadvances.2022009426. ([cited 2024 Jan 3]).CrossRefPubMedPubMedCentral

70.

Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020 Dec 1 [cited 2020 Dec 15];26(12). Available from: https://pubmed.ncbi.nlm.nih.gov/33020644/.

71.

•• Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023 Jan 9 [cited 2024 Jan 3];41(1):210–225.e5. Available from: http://www.cell.com/article/S1535610822005918/fulltext. This study performed comprehensive non-invasive profiling of patient samples before and after CART19 to assess not only ctDNA but also CART19-associated cfDNA. The authors identified genomic alterations associated with treatment resistance and important timepoints of molecular response.

72.

• Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, et al. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 Sep 9 [cited 2024 Jan 3];7(17):4748. Available from: /pmc/articles/PMC10468363/. This study performed clonoSEQ before and after ASCT for R/R DLBCL and demonstrated that detection of MRD from apheresis stem cell samples and in plasma post-transplant were associated with poor outcomes.

73.

Herrera AF, Tracy S, Croft B, Opat S, Ray J, Lovejoy AF, et al. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022 Mar 22 [cited 2023 Mar 29];6(6):1651–60. Available from: https://ashpublications.org/bloodadvances/article/6/6/1651/483728/Risk-profiling-of-patients-with-relapsed.

74.

Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–94. https://doi.org/10.1182/blood-2016-02-699520. ([cited 2024 Jan 4]).CrossRefPubMedPubMedCentral

75.

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238–47.CrossRefPubMed

76.

Liu H, Yang C, Zhao X, Le J, Wu G, Wei J, et al. Genotyping on ctDNA identifies shifts in mutation spectrum between newly diagnosed and relapse/refractory DLBCL. Onco Targets Ther. 2020 [cited 2024 Jan 4];13:10797. Available from: /pmc/articles/PMC7591234/.

77.

Quivoron C, Tarabay A, Michot JM, Pagès A, Lecourt H, Aupérin A, et al. Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma. Haematologica. 2022 Mar 24 [cited 2024 Jan 4];107(8):1928–32. Available from: https://haematologica.org/article/view/haematol.2021.280464.

78.

Zhou L, Zhao H, Shao Y, Chen X, Hong R, Wang L, et al. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. J Cancer. 2021 [cited 2024 Jan 4];12(18):5423–31. Available from: http://www.jcancer.org://creativecommons.org/licenses/by/4.0/.

79.

Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, et al. Primary central nervous system lymphoma. Nature Reviews Disease Primers 2023 9:1. 2023 Jun 15 [cited 2024 Jan 5];9(1):1–19. Available from: https://www.nature.com/articles/s41572-023-00439-0.

80.

Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K. Prevention and management of secondary central nervous system lymphoma. Haematologica. 2023 Mar 1 [cited 2024 Jan 5];108(3):673–89. Available from: https://haematologica.org/article/view/haematol.2022.281457.

81.

Fontanilles M, Marguet F, Bohers É, Viailly PJ, Dubois S, Bertrand P, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017 Jun 1 [cited 2024 Jan 5];8(29):48157–68. Available from: https://www.oncotarget.com/article/18325/text/.

82.

Hattori K, Sakata-Yanagimoto M, Suehara Y, Yokoyama Y, Kato T, Kurita N, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018 Jan 1 [cited 2024 Jan 5];109(1):225–30. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/cas.13450.

83.

Montesinos-Rongen M, Brunn A, Tuchscherer A, Borchmann P, Schorb E, Kasenda B, et al. Analysis of driver mutational hot spots in blood-derived cell-free DNA of patients with primary central nervous system lymphoma obtained before intracerebral biopsy. J Mol Diagn. 2020 Oct 1 [cited 2024 Jan 5];22(10):1300–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32745612/.

84.

Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021 Feb 2 [cited 2024 Jan 5];106(2):513. Available from: /pmc/articles/PMC7849551/.

85.

Olszewski AJ, Chorzalska AD, Petersen M, Ollila TA, Zayac A, Kurt H, et al. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Adv. 2021 Dec 28 [cited 2024 Jan 5];5(24):5525–35. Available from: https://pubmed.ncbi.nlm.nih.gov/34551072/.

86.

•• Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. Journal of Clinical Oncology. 2023;41(9):1684–94. This study proved that with sensitive enough technologies (CAPP-seq and PhasED-seq), CSF and plasma-based ctDNA sequencing is of diagnostic and prognostic utility in CNS lymphomas and can measure response to therapy over time.CrossRefPubMed

87.

Food and Drug Administration. Use of circulating tumor DNA for early-stage solid tumor drug development guidance for industry DRAFT GUIDANCE. 2022 [cited 2022 May 25]; Available from: https://www.fda.gov/media/158072/download.

88.

Stathis A, Hitz F, Schär S, Novak U, Fischer N, Mey U, et al. SAKK 38/19: assessing a CTDNA and pet-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial. Hematol Oncol. 2023 Jun [cited 2023 Nov 2];41(S2):165–6. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3163_T01.

89.

Shah NN, Szabo A, Rajguru S, Devata S, Howard M, Pereira D, et al. Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL). https://doi.org/10.1200/JCO20234116_suppl7554. 2023;41(16_suppl):7554–7554.

90.

Falchi L, Jardin F, Haioun C, Wrobel T, Joergensen JM, Bastos-Oreiro M, et al. Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: preliminary safety and efficacy results. Blood. 2023;142(Supplement 1):858–858. https://doi.org/10.1182/blood-2023-173953.CrossRef

91.

Locke FL, Lekakis LJ, Eradat H, Munoz J, Tees MT, de Vos S, et al. Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). https://doi.org/10.1200/JCO20234116_suppl2517. 2023 May 31 [cited 2024 Jan 25];41(16_suppl):2517–2517. Available from: https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2517.

92.

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. Journal of Clinical Oncology. 2020 May 13 [cited 2020 Aug 9];JCO.19.02104. Available from: https://pubmed.ncbi.nlm.nih.gov/32401634/.

93.

Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan 20 [cited 2024 Jan 5];139(3):413–23. Available from: https://pubmed.ncbi.nlm.nih.gov/34570876/.

94.

Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, et al. High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma. J Clin Oncol. 2023;41(35):5376–87.CrossRefPubMed

95.

Rossi D, Kurtz DM, Roschewski M, Cavalli F, Zucca E, Wilson WH. The development of liquid biopsy for research and clinical practice in lymphomas: report of the 15-ICML workshop on ctDNA. Hematol Oncol. 2020 Feb 1 [cited 2024 Jan 5];38(1):34–7. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2704.

96.

Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology 2022 40:4. 2022 Mar 31 [cited 2024 Jan 5];40(4):585–97. Available from: https://www.nature.com/articles/s41587-022-01222-4.

97.

Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harsløf LBS, Pedersen OB, et al. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics. 2016 Sep 7 [cited 2022 Aug 6];8(1):1–11. Available from: https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-016-0261-y.

Title: Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Authors: Hua-Jay J. Cherng, MD
Alex Herrera, MD
Publication date: 24-04-2024
Publisher: Springer US
Keywords: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Current Treatment Options in Oncology / Issue 5/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-024-01201-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Opinion Statement

Please log in to get access to this content

Other articles of this Issue 5/2024

Photodynamic application in diagnostic procedures and treatment of non-melanoma skin cancers

Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine

HER2-Positive Metastatic Colorectal Cancer

Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?

Role of Metastasis-Directed Therapy in Genitourinary Cancers

Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

Keynote webinar | Spotlight on antibody–drug conjugates in cancer